The most recent National Comprehensive Cancer Network (NCCN) guideline recommendations (Version 5.2021) for the management of NSCLC now include testing for EGFR, BRAF, ALK, ROS1, RET, KRAS, MET exon 14 skipping, and NTRK in nonsquamous lung cancer, as part of broader molecular profiling (8). Here, ALK is linked to non-small cell lung carcinoma.